Candel Therapeutics, Inc. (CADL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Candel Therapeutics, Inc. (CADL) trades at $10.27 with AI Score 54/100 (Grade B). Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. Market cap: $563.83M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for CADL: CADL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CADL against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CADL: 4/7 perspectives are bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Candel Therapeutics, Inc. (CADL) Healthcare & Pipeline Overview
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in immunotherapies for cancer, with a robust pipeline that includes CAN-2409 and CAN-3110, targeting various malignancies and positioning itself as a key player in the oncology treatment landscape.
What Is the Investment Thesis for CADL?
Candel Therapeutics, Inc. presents a compelling investment thesis driven by its innovative pipeline of immunotherapies. With CAN-2409 progressing through multiple clinical trials, the company is positioned to capture significant market share in the oncology sector, particularly in pancreatic and prostate cancers, which represent substantial unmet medical needs. The global cancer immunotherapy market is projected to reach $100 billion by 2026, providing a robust backdrop for Candel's growth. Additionally, the successful completion of clinical trials and subsequent regulatory approvals could lead to lucrative partnerships or acquisitions, enhancing shareholder value. However, investors should remain cognizant of the inherent risks associated with clinical-stage biopharmaceutical companies, including trial outcomes and regulatory hurdles.
Based on FMP financials and quantitative analysis
CADL Key Highlights
- Market Cap of $563.83M reflects investor interest in innovative cancer therapies.
- Phase II/III trials for CAN-2409 indicate strong potential in addressing critical cancer types.
- No dividend yield as the company reinvests in research and development.
- Beta of -0.81 suggests lower volatility compared to the market, appealing to risk-averse investors.
- Small workforce of 38 employees allows for agile decision-making and focused development efforts.
Who Are CADL's Competitors?
CADL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $56.70 | -2.46% | 116B | 88 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 82 |
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CADL's Key Strengths?
- Innovative drug pipeline with multiple candidates in clinical trials.
- Strong focus on immunotherapy, a rapidly growing segment in oncology.
- Experienced leadership team with expertise in biopharmaceuticals.
- Small team allows for agile decision-making and focused development.
What Are CADL's Weaknesses?
- Limited financial resources compared to larger competitors.
- Dependence on the success of clinical trials for future growth.
- No current revenue streams as the company is in clinical stages.
- Small workforce may limit operational capacity and scalability.
What Could Drive CADL Stock Higher?
- Results from Phase II clinical trials for CAN-2409 expected in late 2026, which could validate its efficacy in pancreatic cancer.
- Phase III clinical trials for CAN-2409 in prostate cancer, with potential for significant market impact.
- Initiation of Phase I trials for CAN-3110, targeting recurrent glioblastoma, anticipated in mid-2026.
- Continuous engagement with regulatory bodies to facilitate timely approvals for its therapies.
- Potential strategic partnerships with larger biopharmaceutical firms to enhance development capabilities.
What Are the Key Risks for CADL?
- Negative return on equity (-60.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could delay or derail product development timelines.
- Regulatory hurdles may impact the approval process for new therapies.
- Market competition from established players could limit Candel's market share.
- Dependence on external funding sources for operational sustainability.
What Are the Growth Opportunities for CADL?
- Expansion of CAN-2409: Candel Therapeutics is advancing CAN-2409 through multiple clinical trials, targeting pancreatic, prostate, and lung cancers. The global market for pancreatic cancer therapeutics is expected to grow to $4.5 billion by 2026, presenting a significant opportunity for Candel if the trials yield positive results.
- Development of CAN-3110: As CAN-3110 progresses through Phase I trials for recurrent glioblastoma, it addresses a critical need in a market projected to reach $3 billion by 2025. Successful development could position Candel as a leader in this challenging therapeutic area.
- Strategic partnerships: Candel may seek collaborations with larger biopharmaceutical companies to leverage their resources and distribution networks, enhancing the commercial potential of its therapies. This could lead to accelerated development timelines and increased market reach.
- Regulatory approvals: Achieving FDA and EMA approvals for its therapies could unlock significant revenue streams and enhance Candel's credibility in the market. The timeline for potential approvals could align with the projected growth of the cancer therapy market, providing a timely opportunity.
- Geographic expansion: Candel Therapeutics has the potential to expand its market presence internationally, particularly in emerging markets where cancer treatment options are limited. This could significantly increase its addressable market and revenue potential.
What Opportunities Does CADL Have?
- Expanding market for cancer therapies, particularly immunotherapies.
- Potential for strategic partnerships to enhance development and distribution.
- Increasing demand for innovative cancer treatments in emerging markets.
- Regulatory approvals could significantly boost market presence and revenue.
What Threats Does CADL Face?
- Intense competition from larger biopharmaceutical companies.
- Regulatory challenges and potential delays in clinical trial approvals.
- Market volatility affecting funding and investor sentiment.
- Rapid advancements in cancer treatment could outpace Candel's development.
What Are CADL's Competitive Advantages?
- Innovative pipeline of immunotherapies targeting high unmet needs in oncology.
- Strong focus on clinical trials, enhancing the likelihood of successful product development.
- Experienced leadership team with a track record in biopharmaceutical development.
- Potential for strategic partnerships that can enhance market reach and resource access.
- Niche focus on specific cancer types may provide a competitive edge against larger players.
What Does CADL Do?
Candel Therapeutics, Inc., founded in 2003 and headquartered in Needham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing immunotherapies for cancer patients. Originally known as Advantagene, Inc., the company rebranded in November 2020 to reflect its focus on innovative therapeutic solutions. Candel's lead product candidate, CAN-2409, is currently undergoing Phase II clinical trials for pancreatic cancer, Phase III trials for prostate cancer, and Phase II trials for lung cancer. Additionally, CAN-2409 has completed Phase Ib/II trials for high-grade glioma, showcasing its potential across multiple cancer types. The company is also advancing CAN-3110, which is in Phase I trials for recurrent glioblastoma. With a small but dedicated team of 38 employees, Candel Therapeutics aims to leverage its expertise in immunotherapy to address significant unmet needs in oncology, positioning itself as a forward-thinking entity in the biopharmaceutical landscape.
What Products and Services Does CADL Offer?
- Develops immunotherapies specifically targeting various types of cancer.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Focuses on innovative treatment options for patients with high unmet medical needs.
- Operates primarily in the oncology sector, addressing multiple cancer types.
- Engages in research and development to advance its therapeutic pipeline.
- Seeks partnerships and collaborations to enhance drug development and market reach.
How Does CADL Make Money?
- Generates revenue through the development and commercialization of cancer therapies.
- Secures funding through equity financing and potential partnerships with larger biopharmaceutical companies.
- Invests in research and development to advance its clinical pipeline and bring new therapies to market.
- May receive milestone payments and royalties from partnerships upon successful drug approvals.
- Focuses on creating value through innovative therapies that address significant healthcare needs.
What Industry Does CADL Operate In?
The biotechnology industry, particularly in the oncology sector, is experiencing rapid growth driven by advancements in immunotherapy and personalized medicine. The global cancer immunotherapy market is expected to grow at a CAGR of 15% from 2021 to 2026, reaching approximately $100 billion. Candel Therapeutics, with its focus on immunotherapies, is well-positioned to capitalize on this trend. The competitive landscape includes established players like Bristol-Myers Squibb and Merck, but Candel's targeted approach to specific cancer types may provide a unique advantage in niche markets.
Who Are CADL's Key Customers?
- Primarily targets healthcare providers and oncologists who treat cancer patients.
- Engages with hospitals and cancer treatment centers for clinical trial participation.
- Collaborates with pharmaceutical companies for potential partnerships and licensing agreements.
- Focuses on patients suffering from various types of cancer, particularly those with limited treatment options.
- Works with regulatory bodies to ensure compliance and approval of its therapies.
Company Profile
Candel Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Needham, US. The company is led by CEO Paul-Peter Tak. CADL has traded publicly since 2021.
How Candel Therapeutics, Inc. Is Valued
Candel Therapeutics, Inc. carries a market capitalization of $563.83M, placing it in the small-cap category. Relative to its peer group, CADL's quantitative score of 54/100 is below the peer average of 85/100.
ROE -60%Key Financial Metrics
Return on equity for Candel Therapeutics, Inc. stands at -60.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 28.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Candel Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 3.71 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Candel Therapeutics, Inc. revenue of about $92.5M for fiscal 2026, with EPS near $-0.92. The estimate reflects 6 contributing analysts.
CADL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- La reciente actividad de los insiders muestra un aumento en las compras, lo que indica confianza en el futuro de la empresa.
- El sentimiento de la comunidad ha sido predominantemente positivo, con muchos inversores destacando el potencial innovador de sus tratamientos.
- Las recientes colaboraciones estratégicas con otras instituciones han generado expectativas sobre avances en la investigación y desarrollo.
- El interés en el sector de biotecnología sigue en aumento, lo que podría beneficiar a empresas como Candel Therapeutics.
Bear Case
- Algunos analistas han expresado preocupaciones sobre la sostenibilidad de su modelo de negocio a largo plazo.
- El sentimiento negativo en ciertas plataformas sociales ha aumentado, con algunos inversores dudando de la viabilidad de sus productos.
- Las recientes publicaciones de resultados clínicos han generado incertidumbre, lo que ha afectado la percepción del mercado.
- La competencia en el sector de tratamientos biotecnológicos es feroz, lo que podría limitar el crecimiento de Candel Therapeutics.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
CADL Latest News
No recent news available for CADL.
CADL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CADL.
Price Targets
Wall Street price target analysis for CADL.
CADL MoonshotScore
What does this score mean?
The MoonshotScore rates CADL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul-Peter Tak
CEO
Paul-Peter Tak has extensive experience in the biopharmaceutical industry, having held various leadership roles in drug development and commercialization. He holds a medical degree and a PhD, providing him with a strong foundation in both clinical practice and research. Prior to joining Candel Therapeutics, he served in senior positions at several leading biopharmaceutical companies, where he was instrumental in advancing innovative therapies.
Track Record: Under Paul-Peter Tak's leadership, Candel Therapeutics has successfully advanced its clinical pipeline, including the rebranding from Advantagene, Inc. to Candel Therapeutics. His strategic focus on immunotherapy has positioned the company for future growth in the oncology market.
Common Questions About CADL (Healthcare)
What does Candel Therapeutics, Inc. do?
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer treatment. The company is advancing several product candidates through clinical trials, including CAN-2409 for pancreatic, prostate, and lung cancers, and CAN-3110 for recurrent glioblastoma, aiming to address significant unmet medical needs in oncology.
What do analysts say about CADL stock?
Analysts view Candel Therapeutics, Inc. as a promising player in the biopharmaceutical sector, particularly due to its focus on immunotherapies. Key valuation metrics indicate a market cap of $563.83M, with expectations for growth driven by successful clinical trial outcomes. However, analysts caution about the inherent risks associated with clinical-stage companies, including trial results and regulatory approvals.
What are the main risks for CADL?
Candel Therapeutics, Inc. faces several risks, including the potential for clinical trial failures that could hinder product development and market entry. Regulatory hurdles may also pose challenges in securing timely approvals for its therapies. Additionally, the company competes with larger, established players in the oncology market, which could limit its market share and growth potential.
What are the key factors to evaluate for CADL?
Candel Therapeutics, Inc. (CADL) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does CADL data refresh on this page?
CADL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CADL's recent stock price performance?
Candel Therapeutics, Inc. (CADL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug pipeline with multiple candidates in clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CADL overvalued or undervalued right now?
Valuing Candel Therapeutics, Inc. (CADL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CADL?
Before investing in Candel Therapeutics, Inc. (CADL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is based on publicly available data as of May 2026. Future performance is subject to various risks and uncertainties.